• Investing in the Abandoned

    Jun 4, 2012, 01:00 AM by Michael Croft
    Forbes | When it comes to investing, pharma might point the way to areas of high return--if you take a look at what the sector is abandoning. 
    Full story

  • Genomics-Enabled Prevention

    Jun 4, 2012, 01:00 AM by Michael Croft
    Forbes | Ronald Davis, director of the Stanford Genome Technology Center, believes the time to invest in genomics and personalized medicine is now. 
    Full story

  • Genentech's New and Improved Herceptin

    Jun 4, 2012, 00:00 AM by Michael Croft
    Xconomy | Genentech and ImmunoGen have released early results of an experimental drug, trastuzumab emtansine (T-DM1), that targets HER2-expressing breast cancers. The drug combines the targeting capabilities of Genetech's Herceptin with an additional tumor toxin thanks to a chemical linker from ImmunoGen. 
    Full story

  • Bio-IT World News Briefs: May

    Jun 1, 2012, 01:00 AM by Michael Croft
    Bio-IT World | News briefs and bits from the biotech industry in May.
    Full story

  • Cancer Survivor on N-of-One Direct-to-Patient Ombudsman Model

    May 31, 2012, 09:20 AM by Michael Croft
    Bio-IT World | The long-term success of cancer informatics company N-of-One will be shaped by its newly appointed CEO, strategic partnerships with companies like Foundation Medicine, and ultimately the experiences of cancer patients such as Elaine Waples. 
    Full story

  • The Human Protein Atlas at the GoldLab Symposium

    May 31, 2012, 02:00 AM by Michael Croft
    Bio-IT World | BOULDER, CO—Larry Gold, the founder and CEO of protein biomarker company SomaLogic, hosted a diverse and engaging group of speakers for the third annual GoldLab Symposium* on the future of health care and personalized medicine earlier this month. “Technology is only the penultimate step in successful innovation,” he said. 
    Full story

  • Ensemble, Genentech Development Collaboration

    May 31, 2012, 01:00 AM by Michael Croft
    Mass High Tech | Ensemble Therapeutics and Genentech are collaborating on macrocyclic drug candidates against targets identified by Genentech. The companies will use the Ensemblin collection of macrocycles and Ensemble's proprietary drug discovery platform. 
    Full story

  • GSK Steps Up Bid for Human Genome Sciences

    May 31, 2012, 00:00 AM by Michael Croft
    CNBC | GlaxoSmithKline is hoping to replace the board of Human Genome Sciences with its own representatives, reaching out to executives who could be nominated as "independent" directors. 
    Full story

  • Foundation Medicine Announces First Genomic Profile for Patient Treatment

    May 30, 2012, 04:00 AM by Michael Croft
    Bio-IT World | Foundation Medicine has announced the commercial launch of FoundationOne, the first pan-cancer, fully informative genomic profile designed to help oncologists expand their patients’ treatment options. 
    Full story

  • Computer-Aided Drug Design

    May 30, 2012, 00:05 AM by Michael Croft
    Texas Advanced Computing Center | Drug discovery with 3D help may be a lot more efficient than traditional methods. Researchers at the University of Texas at Austin's Computational Visualization Center have attacked each step of the drug discovery process. 
    Full story

  • Immunogenomics Conference

    May 30, 2012, 00:00 AM by Michael Croft
    Nature | The HudsonAlpha Institute in Huntsville, Ala. is hosting a conference covering immunology, genomics, bioinformatics, and clinical interactions. 
    Full story

  • PCORI’s Research Agenda is Broad, Cost-Neutral

    May 29, 2012, 05:00 AM by Michael Croft
    eCliniqua | The role of cost and patients in comparative effectiveness research (CER) were among the themes of a Post-Approval Summit held earlier this month at Harvard Medical School*. So, too, was the agenda and funding priorities of the latest actor in the CER arena: the independent, multi-stakeholder Patient-Centered Outcomes Research Institute (PCORI). 
    Full story

  • 23andMe Announces First Patent

    May 29, 2012, 03:00 AM by Michael Croft
    The Spittoon | 23andMe CEO and co-founder Anne Wojcicki has announced the company's first patent, expected today: “Polymorphisms Related to Parkinson’s Disease.” The patent relates to the company's discovery of a variant in the SGK1 gene that may be protective against individuals at high risk of Parkinson's thanks to the rare LRRK2 G2019S mutation. 
    Full story

  • Whole Genome Sequencing Sheds Light on Hepatitis Virus Integration in Cancer Genome

    May 29, 2012, 02:05 AM by Michael Croft
    Bio-IT World | Researchers focusing on Asian cancers have used whole-genome sequencing to study the level of hepatitis B virus integration in the genomes of cancer patients and to discover three novel genes associated with recurrent hepatitis B virus integration in hepatocellular carcinoma. The study was published today in Nature Genetics. 
    Full story

  • May 2012 New Products

    May 29, 2012, 02:00 AM by Michael Croft
    Bio-IT World | A summary of the new products in bio-IT released in the past month including NGS sample prep, cloud storage-as-a-service, clinical trial document management, and more. 
    Full story

  • Antipsychotic Shows Anticancer Activity

    May 25, 2012, 03:00 AM by Michael Croft
    Winnipeg Free Press | Canadian researchers screened about 3,000 compounds looking for those that would selectively inhibit cancer stem cells. Of the 20 promising results, one was the antipsychotic drug thioridazine. 
    Full story

  • Singapore Fellowship Offers Up To $2.4m to Individual Researcher

    May 24, 2012, 07:00 AM by Michael Croft
    Bio-IT World | The Singapore National Research Foundation (NRF) Fellowship has released the call for applicants for the sixth annual Singapore NRF Fellowship. The fellowship consists of a five-year research grant of up to $2.4 million to an individual, for research undertaken in Singapore. Fellowship proposals are due by August 15, 2012. 
    Full story

  • Amgen Revives Drug Thanks to Biomarker Data

    May 24, 2012, 02:00 AM by Michael Croft
    Bloomberg | In light of a small set of data, Amgen is reviving its gastric cancer drug rilotumumab that seems to show efficacy for patients with high levels of c-Met, a protein linked to cancer growth. The revival is a win for personalized medicine. 
    Full story

  • Ra Pharmaceuticals Launches Protein-Like Drugs

    May 24, 2012, 01:00 AM by Michael Croft
    Xconomy | Ra Pharmaceuticals is announcing its technology platform to develop protein-like molecules that it calls Cyclomimetrics. The technology was licensed from Uppsala University in Sweden, and makes large molecules that can be made into pills. 
    Full story

  • Personalized Genetic Testing Only for 'Clinical Trial Setting'

    May 24, 2012, 01:00 AM by Michael Croft
    CNN | The American College of Obstetricians and Gynecologists released its recommendation this week that personalized genetic tests be only used in a clinical trial setting, saying the tests are not "ready for prime time." 
    Full story